ValuEngine upgraded shares of Intra-Cellular Therapies (NASDAQ:ITCI) from a hold rating to a buy rating in a research note issued to investors on Thursday.
Several other equities analysts also recently weighed in on ITCI. Zacks Investment Research upgraded Intra-Cellular Therapies from a hold rating to a buy rating and set a $20.00 target price on the stock in a research report on Saturday, January 20th. BidaskClub downgraded Intra-Cellular Therapies from a sell rating to a strong sell rating in a report on Saturday, February 3rd. Royal Bank of Canada began coverage on Intra-Cellular Therapies in a report on Thursday, February 8th. They issued an outperform rating and a $33.00 price objective on the stock. JPMorgan Chase began coverage on Intra-Cellular Therapies in a report on Monday, February 26th. They issued an overweight rating and a $25.00 price objective on the stock. Finally, Cantor Fitzgerald restated a buy rating and issued a $28.00 price objective on shares of Intra-Cellular Therapies in a report on Thursday, March 1st. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $28.27.
NASDAQ ITCI opened at $22.47 on Thursday. Intra-Cellular Therapies has a twelve month low of $9.35 and a twelve month high of $25.82. The stock has a market cap of $1.23 billion, a P/E ratio of -10.60 and a beta of 0.61.
Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.66) by $0.01. Intra-Cellular Therapies had a negative return on equity of 27.67% and a negative net margin of 39,745.53%. analysts predict that Intra-Cellular Therapies will post -3.41 EPS for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in the company. MetLife Investment Advisors LLC raised its holdings in shares of Intra-Cellular Therapies by 15.4% in the 1st quarter. MetLife Investment Advisors LLC now owns 19,606 shares of the biopharmaceutical company’s stock worth $413,000 after purchasing an additional 2,613 shares during the period. Wells Fargo & Company MN grew its stake in shares of Intra-Cellular Therapies by 13.8% in the first quarter. Wells Fargo & Company MN now owns 25,352 shares of the biopharmaceutical company’s stock valued at $534,000 after buying an additional 3,065 shares in the last quarter. Ellington Management Group LLC grew its stake in shares of Intra-Cellular Therapies by 26.9% in the fourth quarter. Ellington Management Group LLC now owns 17,000 shares of the biopharmaceutical company’s stock valued at $246,000 after buying an additional 3,600 shares in the last quarter. Swiss National Bank grew its stake in shares of Intra-Cellular Therapies by 6.4% in the first quarter. Swiss National Bank now owns 74,300 shares of the biopharmaceutical company’s stock valued at $1,564,000 after buying an additional 4,500 shares in the last quarter. Finally, American International Group Inc. grew its stake in shares of Intra-Cellular Therapies by 26.3% in the fourth quarter. American International Group Inc. now owns 28,590 shares of the biopharmaceutical company’s stock valued at $414,000 after buying an additional 5,955 shares in the last quarter. Institutional investors own 68.47% of the company’s stock.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.